Carmella Evans-Molina
Overview
Explore the profile of Carmella Evans-Molina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
171
Citations
4606
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sims E, Cuthbertson D, Ferrat L, Bosi E, Evans-Molina C, DiMeglio L, et al.
Diabetologia
. 2025 Feb;
PMID: 40016443
Aims/hypothesis: Accurate understanding of type 1 diabetes risk is critical for optimisation of counselling, monitoring and interventions, yet even within established staging classifications, individual time to clinical disease varies. Previous...
2.
Peeva E, Guttman-Yassky E, Yamaguchi Y, Berman B, Oemar B, Ramakrishna J, et al.
Drug Discov Today
. 2025 Feb;
30(3):104317.
PMID: 39986647
Evolving research landscapes warrant updates in drug development strategy. Collaborations between pharmaceutical industry and academic institutions are crucial for accelerating drug development, leveraging individual expertise in clinical trial conduct and...
3.
Beli E, Yan Y, Moldovan L, Lydic T, Krishman P, Tersey S, et al.
NPJ Metab Health Dis
. 2025 Feb;
3(1):3.
PMID: 39911696
Strategies to improve metabolic health include calorie restriction, time restricted eating and fasting several days per week or month. These approaches have demonstrated benefits for individuals experiencing obesity, metabolic syndrome,...
4.
Conley J, Jochim A, Evans-Molina C, Watts V, Ren H
Biomolecules
. 2025 Jan;
15(1).
PMID: 39858405
Gut peptides, including glucagon-like peptide-1 (GLP-1), regulate metabolic homeostasis and have emerged as the basis for multiple state-of-the-art diabetes and obesity therapies. We previously showed that G protein-coupled receptor 17...
5.
McCullough M, Letourneau-Freiberg L, Naylor R, Greeley S, Broome D, Tosur M, et al.
J Diabetes Sci Technol
. 2025 Jan;
:19322968241310896.
PMID: 39781649
Monogenic diabetes mellitus (MDM) is a group of relatively rare disorders caused by pathogenic variants in key genes that result in hyperglycemia. Lack of identified cases, along with absent data...
6.
Mohammed S, Bone R, Aquino J, Mirmira R, Evans-Molina C, Ismail H
Islets
. 2024 Dec;
16(1):2436696.
PMID: 39641365
Background: Knockout (KO) ferrets with the cystic fibrosis transmembrane conductance regulator (CFTR) exhibit distinct phases of dysglycemia and pancreatic remodeling prior to cystic fibrosis-related diabetes (CFRD) development. Following normoglycemia during...
7.
8.
Conley J, Jochim A, Evans-Molina C, Watts V, Ren H
bioRxiv
. 2024 Nov;
PMID: 39605686
Gut peptides, including glucagon-like peptide-1 (GLP-1), regulate metabolic homeostasis and have emerged as the basis for multiple state-of-the-art diabetes and obesity therapies. We previously showed that G protein-coupled receptor 17...
9.
Evans-Molina C, Pettway Y, Saunders D, Sharp S, Bate T, Sun H, et al.
bioRxiv
. 2024 Nov;
PMID: 39605606
Phenotyping and genotyping initiatives within the Integrated Islet Distribution Program (IIDP), the largest source of human islets for research in the U.S., provide standardized assessment of islet preparations distributed to...
10.
Galderisi A, Sims E, Evans-Molina C, Petrelli A, Cuthbertson D, Nathan B, et al.
Diabetologia
. 2024 Nov;
68(3):646-661.
PMID: 39560746
Aims/hypothesis: We aimed to analyse TrialNet Anti-CD3 Prevention (TN10) data using oral minimal model (OMM)-derived indices to characterise the natural history of stage 2 type 1 diabetes in placebo-treated individuals,...